| 摘要 |
The present invention aims at providing a novel fused ring compound having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes, more particularly, a compound represented by the formula:
wherein Ar is an optionally substituted cyclic group, ring A is a ring optionally further substituted (provided that the ring is not thiazole, oxazole, imidazole and pyrazole), Xa and Xb are each independently a bond or a spacer having a main chain of 1 to 5 atom(s), Xc is O, S, SO or SO 2 ,
is
ring B is a 5- to 7-membered ring,
Xd is a bond, CH or CH 2 , €¢€¢€¢€¢€¢€¢ is a single bond when Xd is a bond or CH 2 , or a double bond when Xd is CH, and
R 1 is an optionally substituted hydroxy group, and a salt thereof. |
